Cybin is trading 5.4% lower at $10.45 on October 16, 2026, amid pressure on biotech and other risk-sensitive stocks. - XBI is down 2.06%, while major U.S. indexes are also lower. - No company-specific announcement explaining the decline was identified; the October 15 board appointment does not directly explain the drop. - The move points to broader market and sector sentiment rather than a confirmed company catalyst.